Lassa Virus News and Research

RSS
Lassa virus or Lassa viral haemorrhagic fever is an acute illness of 1-4 weeks duration that occurs in West Africa. Though first described in the 1950s, the virus causing the disease was not identified until 1969. The virus is a single-stranded RNA virus belonging to the virus family Arenaviridae. Lassa fever is known to be endemic in Guinea (Conakry), Liberia, Sierra Leone and parts of Nigeria, but probably exists in other West African countries as well.

Further Reading

Remdesivir drug stops novel coronavirus from replicating

Remdesivir drug stops novel coronavirus from replicating

Investigational vaccine protects macaques against four types of hemorrhagic fever viruses

Investigational vaccine protects macaques against four types of hemorrhagic fever viruses

Vaccine for Lassa fever set to enter clinical testing in humans

Vaccine for Lassa fever set to enter clinical testing in humans

Study reveals Lassa virus' soft spot

Study reveals Lassa virus' soft spot

Harvard scientists uncover key mechanism that allows viruses to replicate

Harvard scientists uncover key mechanism that allows viruses to replicate

New disease surveillance tool enables early detection of viral outbreaks

New disease surveillance tool enables early detection of viral outbreaks

A new vaccine shows promise in protecting people from rabies, Lassa fever

A new vaccine shows promise in protecting people from rabies, Lassa fever

New vaccine shows effective protection in animal models of Lassa fever

New vaccine shows effective protection in animal models of Lassa fever

Researchers decipher key component behind rising epidemic of pathogens in West Africa

Researchers decipher key component behind rising epidemic of pathogens in West Africa

Lassa fever epidemic in Nigeria beginning to slow, but concern remains

Lassa fever epidemic in Nigeria beginning to slow, but concern remains

Lassa fever strikes in Nigeria - high rates of fatality with no cure and no vaccine

Lassa fever strikes in Nigeria - high rates of fatality with no cure and no vaccine

Texas Biomed scientists develop new animal model that mimics key features of Zika infection

Texas Biomed scientists develop new animal model that mimics key features of Zika infection

New treatment protects nonhuman primates against Lassa fever eight days after infection

New treatment protects nonhuman primates against Lassa fever eight days after infection

Tulane University receives $12 million NIH grant to develop drug and vaccine against Lassa fever

Tulane University receives $12 million NIH grant to develop drug and vaccine against Lassa fever

Researchers study Lassa fever patient's immune response and viral persistence

Researchers study Lassa fever patient's immune response and viral persistence

Researchers identify key Lassa virus structure using powerful Argonne X-rays

Researchers identify key Lassa virus structure using powerful Argonne X-rays

TSRI study reveals first-ever structure of Lassa virus protein

TSRI study reveals first-ever structure of Lassa virus protein

Researcher aims to eliminate chemotherapy-resistant ovarian tumors using virus treatment

Researcher aims to eliminate chemotherapy-resistant ovarian tumors using virus treatment

New model helps predict outbreaks of zoonotic diseases

New model helps predict outbreaks of zoonotic diseases

TSRI study reveals important traits in LCMV, Lassa virus

TSRI study reveals important traits in LCMV, Lassa virus

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.